This may explain why antibody-mediated general VEGF neutralization, predominantly targeting circulating VEGF, is less efficient than genetic targeting of VEGF in myeloid cells, in particular with regard to increasing endothelial chemerin release and systemic levels that are relevant for the protection against cachexia. This evidence concerns the gene RARRES2 and Cachexia.